Exact Sciences has developed an alternative FDA-approved genetic test to replace less accurate (although previously prevailing) cancer screening blood tests.
Exact Sciences Corp is committed to playing a role in the eradication of colorectal cancer. As part of this mission the Company introduced Cologuard: the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy-to-use screening test they can do in the privacy of their own home.
The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of diseases of the GI tract.
To learn more about Cologuard, visit CologuardTest.com.
To demonstrate its commitment to eradicating colorectal cancer, the Company is partnering with advocacy and healthcare organizations to raise awareness of colorectal cancer screening. Learn more at BeSeenGetScreened.com.